Primary immune deficiencies (PIDs) are a group of rare disorders of the immune system, resulting in increased susceptibility to infections, autoimmunity and malignancies. The most severe forms of PIDs are fatal, unless immune reconstitution is achieved by hematopoietic cell transplantation (HCT), enzyme replacement or gene therapy. Because of the many disease- and treatment-related variables that may affect outcome after HCT, both careful collection of data in Registries and multicenter collaboration are needed to facilitate analysis of outcome and development of prospective clinical trials. In 2009, the Primary Immune Deficiency Treatment Consortium (PIDTC) was established in North America with the goal of building a nation-wide collaboration to carry-out retrospective, cross-sectional and prospective studies that would define risk factors, long term outcomes and late effects in children with Severe Combined Immunodeficiency (SCID), Wiskott-Aldrich Syndrome (WAS) and Chronic Granulomatous Disease (CGD) who receive HCT or other forms of treatment. The proposed annual PIDTC Scientific Workshop will represent a unique and critical forum to assemble experienced and young investigators from all major centers in North America involved in the treatment of these disorders, as well as biostatisticians and Patient Advocacy Groups. The PIDTC Workshop will focus on timely topics to facilitate development of clinical trials aimed at improving treatment of PIDs. The specific objectives of the workshop are as follows: 1) To disseminate information on survival, clinical status, and immune function in patients with severe PIDs who have received HCT or other forms of treatment 2) To initiate data collection and analysis in other forms of severe PIDs that can be treated by HCT 3) To analyze the relevance of biological markers that can predict successful immune reconstitution following HCT 4) To discuss the results of novel approaches to HCT for PID that may minimize transplant-related toxicity while allowing robust and durable engraftment and immune reconstitution 5) To discuss newborn screening for SCID and develop protocols for treating newborn infants diagnosed with SCID. 6) To prompt development of clinical trials in the field of HCT for PIDs 7) To promote education of young investigators with a specific interest in treatment of PIDs 8) To increase synergy among Patient Advocacy Groups actively involved in PID awareness campaigns

Public Health Relevance

Severe forms of congenital Primary immune deficiencies (PIDs) are fatal, unless treated by hematopoietic cell transplantation (HCT), enzyme replacement or gene therapy. In 2009, the Primary Immune Deficiency Treatment Consortium (PIDTC) was established in North America with the goal of building multicenter collaboration to improve outcome in PID patients who receive HCT or other forms of treatment. The proposed annual PIDTC Scientific Workshop will assemble experienced and young investigators from all major centers in North America involved in the treatment of these disorders. Discussion will focus on timely topics to facilitate development of multicenter national and international clinical trials aimed at improving treatment of PIDs. Interaction with Patient Advocacy Groups will promote synergy in PID awareness campaigns.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Conference (R13)
Project #
1R13AI094943-01
Application #
8130081
Study Section
Special Emphasis Panel (ZAI1-BDP-M (J2))
Program Officer
Coulter, Nancy A
Project Start
2011-03-02
Project End
2014-02-28
Budget Start
2011-03-02
Budget End
2012-02-29
Support Year
1
Fiscal Year
2011
Total Cost
$20,000
Indirect Cost
Name
University of California San Francisco
Department
Pediatrics
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Miggelbrink, Alexandra M; Logan, Brent R; Buckley, Rebecca H et al. (2018) B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood 131:2967-2977
Haddad, Elie; Logan, Brent R; Griffith, Linda M et al. (2018) SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood 132:1737-1749
Barzaghi, Federica; Amaya Hernandez, Laura Cristina; Neven, Benedicte et al. (2018) Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. J Allergy Clin Immunol 141:1036-1049.e5
Heimall, Jennifer; Logan, Brent R; Cowan, Morton J et al. (2017) Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. Blood 130:2718-2727
Dvorak, C C; Patel, K; Puck, J M et al. (2017) Unconditioned unrelated donor bone marrow transplantation for IL7R?- and Artemis-deficient SCID. Bone Marrow Transplant 52:1036-1038
Heimall, Jennifer; Puck, Jennifer; Buckley, Rebecca et al. (2017) Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium Biol Blood Marrow Transplant 23:379-387
Wahlstrom, Justin; Patel, Kiran; Eckhert, Erik et al. (2017) Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency. J Allergy Clin Immunol 139:628-633.e10
Heimall, Jennifer; Cowan, Morton J (2017) Long term outcomes of severe combined immunodeficiency: therapy implications. Expert Rev Clin Immunol 13:1029-1040
Hoenig, Manfred; Lagresle-Peyrou, Chantal; Pannicke, Ulrich et al. (2017) Reticular dysgenesis: international survey on clinical presentation, transplantation, and outcome. Blood 129:2928-2938
Dietz, Andrew C; Duncan, Christine N; Alter, Blanche P et al. (2017) The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation f Biol Blood Marrow Transplant 23:24-29

Showing the most recent 10 out of 30 publications